[
  {
    "ts": null,
    "headline": "Vertex to Participate in the UBS Global Healthcare Conference on November 11",
    "summary": "BOSTON, October 27, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the UBS Global Healthcare Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, November 11, 2025, at 10:15 a.m. ET.",
    "url": "https://finnhub.io/api/news?id=337e61dd62bc74f7ae5683bf282f2aa16fb450ec084d4606fcfa1ecfa4a0cab9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761595200,
      "headline": "Vertex to Participate in the UBS Global Healthcare Conference on November 11",
      "id": 137235601,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON, October 27, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the UBS Global Healthcare Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, November 11, 2025, at 10:15 a.m. ET.",
      "url": "https://finnhub.io/api/news?id=337e61dd62bc74f7ae5683bf282f2aa16fb450ec084d4606fcfa1ecfa4a0cab9"
    }
  },
  {
    "ts": null,
    "headline": "Intellia Therapeutics Stock Drops as Safety Fears Emerge in Drug Trial",
    "summary": "The gene-editing biotech  Intellia Therapeutics  said Monday it had paused two trials of one of its lead experimental treatments after a patient was hospitalized due to liver problems.  On an investor call, Intellia’s CEO, John Leonard, said that the company had learned Friday that a patient in a trial of the company’s experimental gene-editing treatment for a heart disease called ATTR-cardiomyopathy had been hospitalized after reporting stomach pain.",
    "url": "https://finnhub.io/api/news?id=0532335a327feb18874c46c311864a47a4d46a3ce51288f4ca7ee33e158e2b08",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761580980,
      "headline": "Intellia Therapeutics Stock Drops as Safety Fears Emerge in Drug Trial",
      "id": 137231095,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The gene-editing biotech  Intellia Therapeutics  said Monday it had paused two trials of one of its lead experimental treatments after a patient was hospitalized due to liver problems.  On an investor call, Intellia’s CEO, John Leonard, said that the company had learned Friday that a patient in a trial of the company’s experimental gene-editing treatment for a heart disease called ATTR-cardiomyopathy had been hospitalized after reporting stomach pain.",
      "url": "https://finnhub.io/api/news?id=0532335a327feb18874c46c311864a47a4d46a3ce51288f4ca7ee33e158e2b08"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?",
    "summary": "Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=fcf271de2f98a74d48c56dd15d5b73e0c04b863d010a39d227a6dcb7ddf84bf5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761573619,
      "headline": "Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?",
      "id": 137228837,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=fcf271de2f98a74d48c56dd15d5b73e0c04b863d010a39d227a6dcb7ddf84bf5"
    }
  },
  {
    "ts": null,
    "headline": "How to Find Strong Medical Stocks Slated for Positive Earnings Surprises",
    "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
    "url": "https://finnhub.io/api/news?id=f49e1e2eaf000a14d46f10eef8703b00f9e668a76360237f5c5a1ae5e2434e12",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761570003,
      "headline": "How to Find Strong Medical Stocks Slated for Positive Earnings Surprises",
      "id": 137228838,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
      "url": "https://finnhub.io/api/news?id=f49e1e2eaf000a14d46f10eef8703b00f9e668a76360237f5c5a1ae5e2434e12"
    }
  },
  {
    "ts": null,
    "headline": "Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030",
    "summary": "Vertex appears to be by far the better buy right now.",
    "url": "https://finnhub.io/api/news?id=8852232a228289b06516240d36fffe2ab383726f295a627ec84fbfee93ca8dcd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761558180,
      "headline": "Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030",
      "id": 137228788,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex appears to be by far the better buy right now.",
      "url": "https://finnhub.io/api/news?id=8852232a228289b06516240d36fffe2ab383726f295a627ec84fbfee93ca8dcd"
    }
  }
]